Pharmaceuticals

Adial Pharmaceuticals

Adial Pharmaceuticals released FY2026 Q1 earnings on May 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.4799 (forecast USD -2.73)

Adial Pharmaceuticals released FY2025 Annual Earnings on March 5 (EST), Actual Revenue: USD 0 (Forecast: USD 0), Actual EPS: USD -11.9306 (Forecast: USD -11.1066)

Adial Pharmaceuticals released FY2025 Q4 earnings on March 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.8245 (forecast USD -2.13)

Adial Pharmaceuticals Announces Q3 2025 Financial Results and Advances AD04 Development

Adial Pharmaceuticals released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.0224 (forecast USD -3.5)

Adial Pharmaceuticals released FY2025 9 Months Earnings on November 13, 2025 (EST) with actual revenue of USD 0 and EPS of USD -15.152

Jason McCarthy Gives Adial Pharmaceuticals a Buy Rating

Adial Pharmaceuticals released FY2025 Semi-Annual earnings on August 13, 2025 (EST), with actual revenue of USD 0 and EPS of USD -12.1831

Adial Pharmaceuticals released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.6093 (forecast USD -5.5)

Adial Pharmaceuticals Announces Submission of Important Documents

Adial Pharmaceuticals signs AD04 production agreements with Cambrex and Thermo Fisher

Adial Pharmaceuticals' AD04 Phase III Clinical Trial Makes Progress

Adial Pharmaceuticals Registers About 6.73 Million Shares for Shareholder Resale

Adial Pharmaceuticals Reports Reduced Q1 Net Loss

Adial Pharmaceuticals released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -8.5202 (forecast USD -12.375)

Adial Pharmaceuticals Inc Expected to Report Q1 EPS Loss of 49 Cents

Adial Pharmaceuticals Inc expects to report a loss of 49 cents per share

Adial Pharmaceuticals Granted FDA Approval to Hold End-of-Phase 2 Meeting

Adial Pharmaceuticals Conducts Warrant Transaction to Raise $2.75 Million

Adial Obtains Patent for AD04 to Treat Alcohol-Related Conditions

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

ADIL

BDTX

EDSA

CODX

MTVA

IBBQ

LABU

SBIO

ARKG

In Tuesday's trading, biotech stocks saw significant gains. MetaVia Inc. (MTVA) surged over 69% as it advances its obesity treatment DA-1726. Co-Diagnostics Inc. (CODX) rose 43% after completing an assay for the Ebola virus. Edesa Biotech Inc. (EDSA) gained over 33% ahead of new data on Paridiprubart for acute kidney injury. Adial Pharmaceuticals Inc. (ADIL) increased nearly 28% with its AUD treatment, while Black Diamond Therapeutics Inc. (BDTX) was up 16% before presenting Phase 2 trial results.

rttnews

Black Diamond Therapeutics

Edesa Biotech

Co-Diagnostics

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch

Analyst Jason McCarthy of Maxim Group has reiterated a Buy rating on Adial Pharmaceuticals, maintaining an $8 price target. He highlights the potential of AD04’s precision strategy for alcohol use disorder, which targets patients unresponsive to current therapies. The recent submission of AD04 to the FDA’s pilot program could expedite regulatory review. Despite funding challenges, McCarthy sees an attractive risk-reward profile. ADIL’s stock has surged 320.73% over the past six months, rising from $0.328 to $1.380.

Tip Ranks

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

iShares US Pharma

Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained

ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov | ADIA Stock News

StockTitan

ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov | ADIA Stock News

Adial Pharma (ADIL) is exploring strategic alternatives, including mergers and asset sales, but faces risks that any deal may not be favorable or timely. The company's share price may reflect expectations of a transaction, and failure to complete one could lead to negative investor sentiment and a decline in stock price. This situation could hinder Adial's access to capital markets and impact its long-term prospects. Currently, Wall Street rates ADIL stock as a Moderate Buy based on one Buy recommendation.

Adial Pharma’s Strategic Options: High-Stakes Search for a Deal Puts Share Price and Long-Term Prospects at Risk

BMRN

VRTX

Alebund Pharmaceuticals has completed patient enrollment in its global Phase III clinical trial for AP301, a novel treatment for hyperphosphatemia in chronic kidney disease patients. The trial enrolled 282 patients across the U.S. and China, exceeding the target of 264. AP301 aims to improve phosphate-binding capability and patient adherence compared to existing treatments. The trial's primary endpoint is the change in serum phosphate levels, with results expected to support U.S. registration of AP301. Hyperphosphatemia is a common complication in CKD patients, significantly impacting their health outcomes.

prnewswire

BioMarin Pharma

Vertex Pharma

00:00 ETAlebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia

Adial Pharmaceuticals has filed a new U.S. utility patent application for its lead investigational drug, AD04, aimed at treating Alcohol Use Disorder (AUD) in heavy drinkers. This patent, if granted, is expected to protect the company's core assets until at least 2045. The application includes a request for expedited examination to enhance strategic positioning for potential commercialization and licensing discussions. CEO Cary Claiborne emphasized the importance of this step in maximizing asset value and strengthening negotiating positions with partners.

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 | ADIL Stock News

Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program | ADIL Stock News

Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program | ADIL Stock News

Adial Pharmaceuticals(ADIL.US)

MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch

Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained

ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov | ADIA Stock News

Adial Pharma’s Strategic Options: High-Stakes Search for a Deal Puts Share Price and Long-Term Prospects at Risk

00:00 ETAlebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 | ADIL Stock News

Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program | ADIL Stock News